NovoCure LimitedNVCR
Sell someDon't buy more at this price.
- 2 good· Earnings beat
- 4 to watch· Revenue slowing
$11.75−0.24 (−2.00%)
Price at 3:03 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETNASDAQ · Healthcare · Small company
Read the full report on NVCR with a free account
The full report adds the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
+4.3% in a yearsince Nov 10, 2025
The news behind our call
written Tuesday, 9:32 AM ETTuesday, 9:32 AM ET · 7 articles · 5 sources
The page displays a press-and-hold human-verification prompt.
NovoCure’s recent earnings beat and projected profit growth give shareholders operating support.
What changed
From Yahoo Finance, NovoCure Limited via Nasdaq, NovoCure Limited via Yahoo Finance and 2 more
Overview
In plain numbers
- Revenue grew 12.9% from a year earlier, to $725.4M in the last twelve months.
- It loses 16 cents on every revenue dollar at the operating line, down from a loss of 8 cents in FY 2021.
- It burned $24.6M of free cash in the last twelve months.
- It holds $463.5M in cash and investments against $231.6M of debt, which leaves $231.9M of net cash.
Key figures
- Revenue (TTM)
- $725M
- Revenue growth, 1 year
- +12.9%
- Net income
- −$122M
- EPS (diluted)
- −$1.06
- Gross margin
- 77.3%
- Operating margin
- -16.4%
- Return on equity
- -35.2%
- Return on capital
- -95.4%
- Debt / equity
- 0.66
- Current ratio
- 2.49
- Buyback yield
- -3.87%
Key facts
- Company value
- $1.6B
- Today's range
- 11.6312.10
- Past year's range
- 10.0319.99
- Yesterday's close
- $11.99